# Stablix, Inc.

> Stablix, Inc. is a preclinical biopharmaceutical company pioneering targeted protein stabilization (TPS), a new therapeutic modality that does the opposite of protein degraders. Its RESTORE platform generates heterobifunctional small molecules called RESTORACs that recruit deubiquitinase enzymes (DUBs) to selectively remove ubiquitin from disease-relevant proteins, restoring deficient proteins to therapeutic levels or correcting aberrant protein function. Co-located in New York City and Boston and founded on science from Columbia University, Stablix has raised roughly $78M and is developing programs in cancer, rare diseases and immunological disorders, including a strategic collaboration with Vertex Pharmaceuticals.

- **Founded:** 2021
- **Headquarters:** New York, New York, United States
- **Founders:** Henry Colecraft (Co-Founder & Chair of Scientific Advisory Board (Columbia University professor)), Scott Kanner (Co-Founder & Scientific Advisor)
- **Team size:** ~16 employees
- **Products:** RESTORE Platform, RESTORAC molecules, Preclinical pipeline
- **Notable:** Launched in 2021 with a $63M Series A led by Versant Ventures, Raised approximately $78M in total funding to date, Established targeted protein stabilization / targeted deubiquitination as a named new therapeutic field

## Products & services

- **RESTORE Platform** — A drug discovery platform that designs heterobifunctional small molecules to selectively recruit active deubiquitinases (DUBs) to a target protein, precisely removing ubiquitin to stabilize or increase the protein's levels and activity.
- **RESTORAC molecules** — The heterobifunctional small molecules produced by the platform. Each RESTORAC bridges a chosen target protein to a deubiquitinase, editing ubiquitin to restore deficient proteins to therapeutic levels or correct aberrant function.
- **Preclinical pipeline** — Discovery-stage programs applying targeted protein stabilization to cancer, rare diseases and immunological disorders. Specific development candidates are not yet publicly disclosed.

## Achievements

- Launched in 2021 with a $63M Series A led by Versant Ventures
- Raised approximately $78M in total funding to date
- Established targeted protein stabilization / targeted deubiquitination as a named new therapeutic field
- Signed a strategic collaboration and license agreement with Vertex Pharmaceuticals in April 2023
- Translated academic science from Columbia University into a venture-backed platform company

## Latest updates

- **2023-04** — Announced strategic collaboration and license agreement with Vertex Pharmaceuticals to discover and develop RESTORAC molecules for targeted protein stabilization.
- **2022-11** — Latest funding tranche of approximately $15M (Series A), bringing total funding toward ~$78M.
- **2021-06** — Emerged from stealth with a $63M Series A financing to advance the RESTORE platform.

## Links

- Website: https://stablix.com
- LinkedIn: https://www.linkedin.com/company/stablix
- Twitter/X: https://twitter.com/StablixInc

---

Profile page: https://yespress.io/stablix-inc
Published by YesPress — https://yespress.io
Last updated: 2026-07-18